Biophysics Centre of Excellence
Specialized biophysics infrastructure bridging AI-experimentation gap in drug discovery
Service · HybridCompany source
Company profile
About Arctoris
Arctoris is a Partnership Research Organisation (PRO) that accelerates drug discovery by combining robotics, data science, and deep biological expertise to generate precise, reproducible, and AI-ready data. Founded at the University of Oxford, the company was established to solve a fundamental problem: biology has not kept pace with the scale, rigor, and data quality modern science demands. At the heart of Arctoris is Ulysses®, a fully robotic, cloud-controlled discovery platform that runs entire assay cascades across biochemistry, biophysics, cell biology, and structural biology. The platform captures every action, parameter, and datapoint in real time, producing highly reproducible, FAIR-compliant datasets at a scale and consistency conventional CROs cannot match. Arctoris operates as a true extension of partners' teams, combining world-class scientists with a data-first automation platform to design bespoke experimental strategies and solve complex biological problems collaboratively. The company recently launched a Biophysics Centre of Excellence to bridge the AI-experimentation gap in drug discovery. Arctoris serves biotech, techbio, and pharmaceutical companies, delivering data that scientists, regulators, and machine-learning systems can trust from day one.
Company description Arctoris official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Arctoris?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- breast cancer
- cancer
- CNS diseases
- COVID-19
- heart disease
- lung cancer
Who it serves
- Biotech
- Pharma
- Techbio
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Geographic context
Marketsinternational · United Kingdom
Company sourceOfficial website
Company milestones
Platform expansion
Launched Biophysics Centre of Excellence to bridge AI-experimentation gap in drug discovery. Acquired Eli Lilly's Life Sciences Studio automated robotic laboratory. Partnered with 310.ai to pioneer AI-designed proteins for cardiac therapy. Grew workforce by over 100%.
Partnerships
Recorded partners
- 310.ai
- Alzheimer's Research UK Oxford Drug Discovery Institute
- Eli Lilly (acquired Life Sciences Studio)
- IBM Research
- Insilico Medicine
- Intelligent OMICS
- King's College London
- Medicines Discovery Catapult
- Molecule
- Origami Therapeutics
- University of Cambridge
- University of Oxford
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Ulysses®
Fully robotic, cloud-controlled drug discovery platform for automated wet lab biology R&D
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
A pivot-tether model for nucleosome recognition by the chromosomal passenger complex.EMBO reports · Sep 1, 2025
Therapeutic safety implications of SARM1 active site inhibitors: subinhibitory concentrations cause neurodegeneration.npj drug discovery · Aug 25, 2025
Data standards in drug discovery: A long way to go.Drug discovery today · Feb 1, 2024
Author Correction: Artificial intelligence driven design of catalysts and materials for ring opening polymerization using a domain-specific language.Nature communications · Jul 25, 2023
Artificial intelligence driven design of catalysts and materials for ring opening polymerization using a domain-specific language.Nature communications · Jun 21, 2023
AI in drug discovery: Applications, opportunities, and challenges.Patterns (New York, N.Y.) · Jun 10, 2022
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
reproducible, FAIR-compliant datasets
generated at scale and consistency conventional CROs cannot match
AI-ready data
designed for machine learning and regulatory systems from day one
310.ai
Partnership to pioneer AI-designed proteins for cardiac therapy
IBM Research
Collaboration advancing fully autonomous, closed-loop molecular discovery platform targeting Janus kinase
Insilico Medicine
Technology partnership combining robotics and AI for COVID-19 drug discovery
Intelligent OMICS and Medicines Discovery Catapult
AI-driven drug discovery collaboration for lung cancer therapeutics
University of Cambridge and King's College London
Collaboration demonstrating how artificial intelligence advances drug discovery
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Tom Fleming
Founder and CEO
Florence Eustache
Chief Business Officer
Paul Custance
Chief Financial Officer
Poppy Roworth
Chief Operating Officer
Sally Cullen
Chief People Officer
06 · Company updates
Updates from Arctoris
Recent articles published on Arctoris's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.